Although traditionally reserved to render inoperable disease operable, neoadjuvant chemotherapy is increasingly being used to improve the chance for breast-conserving surgery, to gain information on pathologic response rates for a more rapid assessment of new chemotherapy-biologic regimens, and also to study in vivo tumour sensitivity or resistance
to the agent being used. Similarly, use of neoadjuvant endocrine treatment was also traditionally restricted to elderly or frail patients who were felt to be unsuitable for chemotherapy. It is therefore not surprising HSP990 that, given the increasing realization of the pivotal role of endocrine therapy in patient care, there is enhanced interest in neoadjuvant endocrine therapy not only as a less-toxic alternative to chemotherapy, but also to assess tumour sensitivity or resistance to endocrine agents. The availability of newer endocrine manipulations and increasing evidence that the benefits of chemotherapy are frequently marginal in many hormone-positive patients is making endocrine
therapy increasingly important in the clinical setting. The hope is that, one day, instead of preoperative endocrine therapy being restricted to the infirm and the elderly, it will be used in the time between biopsy diagnosis and surgery to predict which patients will or will not benefit from chemotherapy in the adjuvant setting.”
“Whether cytokines can influence selleckchem the adaptive immune response by antigen-specific
gamma delta Mocetinostat nmr T cells during infections or vaccinations remains unknown. We previously demonstrated that, during BCG/Mycobacterium tuberculosis (Mtb) infections, Th17-related cytokines markedly upregulated when phosphoantigen-specific V gamma 2V delta 2 T cells expanded. In this study, we examined the involvement of Th17-related cytokines in the recall-like responses of V gamma 2V delta 2 T cells following Mtb infection or vaccination against TB. Treatment with IL-17A/IL-17F or IL-22 expanded phosphoantigen 4-hydroxy-3-methyl-but-enyl pyrophosphate (HMBPP)-stimulated V gamma 2V delta 2 T cells from BCG-vaccinated macaques but not from naive animals, and IL-23 induced greater expansion than the other Th17-related cytokines. Consistently, Mtb infection of macaques also enhanced the ability of IL-17/IL-22 or IL-23 to expand HMBPP-stimulated V gamma 2V delta 2 T cells. When evaluating IL-23 signaling as a prototype, we found that HMBPP/IL-23-expanded V gamma 2V delta 2 T cells from macaques infected with Mtb or vaccinated with BCG or Listeria-actA prfA*-ESAT6/Ag85B produced IL-17, IL-22, IL-2, and IFN-gamma. Interestingly, HMBPP/IL-23-induced production of IFN-gamma in turn facilitated IL-23-induced expansion of HMBPP-activated V gamma 2V delta 2 T cells.